Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TKT | P29401 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12926350 | 0.83 | NOS3 (0.48) | KDM4ETKTIDO1POLBNOS3 | |
| SCHEMBL14385061 | 0.83 | NOS3 (0.39) | DPP4NOS3NOS1NOS2TDP1 | |
| SCHEMBL318830 | 0.81 | KDM4E (0.46) | KDM4ETKTIDO1POLBNOS3 | |
| SCHEMBL317561 | 0.81 | TKT (0.49) | KDM4ETKTIDO1POLBNOS3 | |
| SCHEMBL317560 | 0.81 | KDM4E (0.46) | KDM4ETKTIDO1POLBNOS3 | |
| SCHEMBL18368343 | 0.80 | POLB (0.38) | KDM4EIDO1DPP4POLBNOS3 | |
| SCHEMBL19503881 | 0.78 | KDM4E (0.47) | KDM4ETKTIDO1NOS3NOS1 | |
| SCHEMBL12499744 | 0.77 | POLB (0.40) | KDM4ETKTIDO1DPP4POLB | |
| SCHEMBL28157795 | 0.77 | POLB (0.36) | KDM4ETKTIDO1POLBNOS3 | |
| SCHEMBL10288727 | 0.75 | KDM4E (0.41) | KDM4ETKTIDO1POLBNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | claimed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | claimed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | claimed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | claimed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | claimed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | claimed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | claimed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | claimed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | KDM4E 59/4885TKT 2810/4885IDO1 2529/4885 |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | KDM4E 4828/4885TKT 2861/4885IDO1 1797/4885 |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | KDM4E 59/4885TKT 2810/4885IDO1 2529/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | KDM4E 4866/4885TKT 2603/4885IDO1 2701/4885 |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | KDM4E 59/4885TKT 2810/4885IDO1 2529/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | KDM4E 4853/4885TKT 2235/4885IDO1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.